kawasaki disease · pediatric cardiology s. kristen sexson tejtel, md, phd, mph pediatric...
TRANSCRIPT
![Page 1: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/1.jpg)
Pediatric Cardiology
S. Kristen Sexson Tejtel, MD, PhD, MPHPediatric Preventive Cardiology
TCHAPP ConferenceApril 4, 2019
Kawasaki Disease:What you need to know from the 2017 Guidelines
No disclosures to report
![Page 2: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/2.jpg)
Page 1
xxx00.#####.ppt 4/10/19 10:37:31 AMPediatric Cardiology Pediatric
•History of KD/Epidemiology
•2017 Guidelines- Diagnosis –
• Classic cases • The challenges of diagnosis• Echocardiography in KD• Need for additional imaging
- Treatment• The future of initial KD therapy• IVIG resistance - Knowing when to retreat• Complex cases
• KDSS• KD with severe coronary artery aneurysms• Persistent features without fever
• Thromboprophylaxis in KD- Follow-up
• When to follow-up• Immunizations after IVIG for KD
Outline
![Page 3: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/3.jpg)
Page 2
xxx00.#####.ppt 4/10/19 10:37:32 AMPediatric Cardiology Pediatric
•Ka·wa·sa·ki dis·ease - noun
•a disease of unknown cause, occurring primarily in young children and giving rise to a rash, glandular swelling, and sometimes damage to the heart.
What is Kawasaki Disease (KD)?
![Page 4: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/4.jpg)
Page 3
xxx00.#####.ppt 4/10/19 10:37:33 AMPediatric Cardiology Pediatric
• Etiology: Infection? à Infectious Disease?
• Diagnosis/Treatmentà Pediatrics/Hospitalists?
• Pathophysiology: Vasculitis à Rheumatology?
• Consequence: Coronary Aneurysms à Cardiology?
Who “Owns” KD?
![Page 5: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/5.jpg)
Page 4
xxx00.#####.ppt 4/10/19 10:37:33 AMPediatric Cardiology Pediatric
Kawasaki Disease (KD) History
![Page 6: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/6.jpg)
Page 5
xxx00.#####.ppt 4/10/19 10:37:34 AMPediatric Cardiology Pediatric
•Annual US incidence ~25 per 100,000 children <5yrs old
•80-90% of cases occur in children <5yrs old•Peak 18-24 mo
•Rare beyond late childhood•Older children may experience delays in diagnosis
•Boys > Girls (1.5:1)
Epidemiology
![Page 7: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/7.jpg)
Page 6
xxx00.#####.ppt 4/10/19 10:37:35 AMPediatric Cardiology Pediatric
•Japan: •10x increased risk with an affected sibling
•2x increased risk with a previously affected parent
Epidemiology
![Page 8: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/8.jpg)
Page 7
xxx00.#####.ppt 4/10/19 10:37:36 AMPediatric Cardiology Pediatric
Pathophysiology
![Page 9: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/9.jpg)
Page 8
xxx00.#####.ppt 4/10/19 10:37:37 AMPediatric Cardiology Pediatric
Complete KD
![Page 10: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/10.jpg)
Page 9
xxx00.#####.ppt 4/10/19 10:37:37 AMPediatric Cardiology Pediatric
![Page 11: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/11.jpg)
Page 10
xxx00.#####.ppt 4/10/19 10:37:38 AMPediatric Cardiology Pediatric
![Page 12: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/12.jpg)
Page 11
xxx00.#####.ppt 4/10/19 10:37:39 AMPediatric Cardiology Pediatric
![Page 13: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/13.jpg)
Page 12
xxx00.#####.ppt 4/10/19 10:37:39 AMPediatric Cardiology Pediatric
![Page 14: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/14.jpg)
Page 13
xxx00.#####.ppt 4/10/19 10:37:40 AMPediatric Cardiology Pediatric
![Page 15: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/15.jpg)
Page 14
xxx00.#####.ppt 4/10/19 10:37:41 AMPediatric Cardiology Pediatric
IRRITABILITY
![Page 16: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/16.jpg)
Page 15
xxx00.#####.ppt 4/10/19 10:37:42 AMPediatric Cardiology Pediatric
•Systemic inflammation of medium-sized arteries and multiple organs
•Associated clinical findings:- liver (hepatitis), - lung (interstitial pneumonitis), -gastrointestinal tract (abdominal pain, vomiting, diarrhea, gallbladder hydrops), -meninges (aseptic meningitis, irritability),-heart (myocarditis, pericarditis, valvulitis), -urinary tract (pyuria), -pancreas (pancreatitis), - lymph nodes (lymphadenopathy).
KD Characteristics
![Page 17: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/17.jpg)
Page 16
xxx00.#####.ppt 4/10/19 10:37:42 AMPediatric Cardiology Pediatric
•The signs are common
•There is no gold standard lab test
•The stakes are high
•A missed diagnosis may manifest years (or decades) later
•However, are we over-diagnosing?
The Challenges of Diagnosis
![Page 18: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/18.jpg)
Page 17
xxx00.#####.ppt 4/10/19 10:37:43 AMPediatric Cardiology Pediatric
•How about incomplete KD?
The Challenges of Diagnosis
![Page 19: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/19.jpg)
Page 18
xxx00.#####.ppt 4/10/19 10:37:44 AMPediatric Cardiology Pediatric
2017 Guideline
![Page 20: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/20.jpg)
Page 19
xxx00.#####.ppt 4/10/19 10:37:45 AMPediatric Cardiology Pediatric
Echo in KD
![Page 21: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/21.jpg)
Page 20
xxx00.#####.ppt 4/10/19 10:37:46 AMPediatric Cardiology Pediatric
•Any of 3 conditions are met: -Z score of LAD or RCA ≥2.5
-Coronary artery aneurysm
-≥3 other suggestive features:
•decreased left ventricular function
•mitral regurgitation
•pericardial effusion
•Z scores in the LAD or RCA of 2 to 2.5
2017 Guidelines –What Defines a Positive Echocardiogram?
![Page 22: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/22.jpg)
Page 21
xxx00.#####.ppt 4/10/19 10:37:47 AMPediatric Cardiology Pediatric
•Summary:1. Echobrightness
2. Ectasia
3. Lack of distal tapering
4. Dilation
5. Aneurysm formation
6. Valve regurgitation
7. Aortic root involvement
8. Function
9. Pericardial Effusion
TCH KD Echo Read
![Page 23: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/23.jpg)
Page 22
xxx00.#####.ppt 4/10/19 10:37:47 AMPediatric Cardiology Pediatric
•Z-Score Classification – Risk Level1. No involvement: Always <22. Dilation only: 2 to <2.5; or if initially <2, a decrease in Z
score during follow-up ≥1
3. Small aneurysm: ≥2.5 to <54. Medium aneurysm: ≥5 to <10, and absolute5. dimension <8 mm6. Large or giant aneurysm: ≥10, or absolute dimension ≥8
mm
Coronary Artery Involvement
![Page 24: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/24.jpg)
Page 23
xxx00.#####.ppt 4/10/19 10:37:48 AMPediatric Cardiology Pediatric
Assessing Aneurysms
![Page 25: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/25.jpg)
Page 24
xxx00.#####.ppt 4/10/19 10:37:49 AMPediatric Cardiology Pediatric
Giant Aneurysms and Prognosis
•Patients with giant aneurysms have worst prognosis
•30 year survival- 90%•Only 36% cardiac event free
(Tsuda et al AM Heart J 2014; 167: 249-58)(Manlhoit/PHN Pediatr Cardiol 2010)
![Page 26: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/26.jpg)
Page 25
xxx00.#####.ppt 4/10/19 10:37:50 AMPediatric Cardiology Pediatric
•Summary:1. Echobrightness
2. Ectasia
3. Lack of distal tapering
4. Dilation
5. Aneurysm formation
6. Valve regurgitation
7. Aortic root involvement
8. Function9. Pericardial Effusion
Kawasaki Echo Read
![Page 27: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/27.jpg)
Page 26
xxx00.#####.ppt 4/10/19 10:37:51 AMPediatric Cardiology Pediatric
•It is reasonable to obtain advanced imaging studies -computed tomographic angiography (CTA)-cardiac magnetic resonance imaging (CMRI)- invasive angiography
•Recommended on patients with:-severe proximal coronary artery abnormalities -when management decisions depend on visualization of distal segments -difficult to be seen by echocardiography
•Other vasculature can be imaged simultaneously
2017 Guidelines –Advanced Imaging in KD
![Page 28: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/28.jpg)
Page 27
xxx00.#####.ppt 4/10/19 10:37:51 AMPediatric Cardiology Pediatric
•MR in KD-Demonstrates distal aneurysms
-Viability/delayed enhancement
-Myocardial perfusion
-See extracardiac dilation
-Frequently need anesthesia
•CT in KD-Better than MR for thrombus evaluation-Smaller slices than MRI-Down side: Radiation
![Page 29: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/29.jpg)
Page 28
xxx00.#####.ppt 4/10/19 10:37:52 AMPediatric Cardiology Pediatric
Catheterization in KD
![Page 30: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/30.jpg)
Page 29
xxx00.#####.ppt 4/10/19 10:37:53 AMPediatric Cardiology
Goal of Therapy •Decrease systemic inflammation
•Prevent coronary aneurysms
•Minimize peak dimensions of coronary aneursysm(s)
•Prevent coronary thrombosis
![Page 31: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/31.jpg)
Page 30
xxx00.#####.ppt 4/10/19 10:37:54 AMPediatric Cardiology Pediatric
•2017 Guideline states- IVIG
•“Patients with complete and incomplete KD should be treated with high-dose IVIG (2 g/kg)”
-Aspirin:
•“Administration of moderate (30 – 50 mg/kg/day) to high dose (80 – 100 mg/kg/day) ASA is reasonable until the patient is afebrile, although there is no evidence that it reduces coronary artery aneurysms”
The Future of Initial KD Treatment
![Page 32: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/32.jpg)
Page 31
xxx00.#####.ppt 4/10/19 10:37:54 AMPediatric Cardiology Pediatric
•What about steroids?-Traditionally has been a controversial topic
-But should we consider steroids as part of initial therapy?
The Future of Initial KD Treatment
![Page 33: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/33.jpg)
Page 32
xxx00.#####.ppt 4/10/19 10:37:55 AMPediatric Cardiology Pediatric
•2017 Guideline states
-“Single-dose pulse methylprednisolone should not be administered with IVIG as routine primary therapy”
-“A longer course of corticosteroids (tapering over 2 – 3 weeks), together with IVIG and ASA may be considered for treatment of high-risk patients when such high risk can be identified in patients before initiation of treatment”
The Future of Initial KD Treatment
![Page 34: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/34.jpg)
Page 33
xxx00.#####.ppt 4/10/19 10:37:56 AMPediatric Cardiology Pediatric
•2017 Guideline states…-“Approximately 10 – 20% of patients with KD develop recrudescent or persistent fever at least 36 hours after the end of their IVIG infusion and are termed IVIG resistant.”
When to Retreat?
![Page 35: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/35.jpg)
Page 34
xxx00.#####.ppt 4/10/19 10:37:56 AMPediatric Cardiology Pediatric
IVIG resistance - Pathophysiology
![Page 36: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/36.jpg)
Page 35
xxx00.#####.ppt 4/10/19 10:37:57 AMPediatric Cardiology Pediatric
2017 Guidelines - IVIG Resistance1. Second dose of IVIG (2 g/kg) after 36 hours
2. Methylprednisolone 20–30 mg/kg IV x 3 days, +/- taper of oral steroids
Second dose of IVIG (2 g/kg), IV steroids x 3 days, +/-taper of oral steroids
3. Second dose of IVIG (2 g/kg) with prolonged oral taper of prednisolone/prednisone
4. Infliximab (5 mg/kg) instead of 2nd IVIG or corticosteroidsBrian W. McCrindle et al. Circulation. 2017;135:e927-e999
OR
OR
OR
OR
![Page 37: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/37.jpg)
Page 36
xxx00.#####.ppt 4/10/19 10:37:58 AMPediatric Cardiology Pediatric
5. Cyclosporine in those who have failed above
6. Highly refractory patients
- Anakinra
- Cyclophosphamide
- Plasma exchange
Brian W. McCrindle et al. Circulation. 2017;135:e927-e999
2017 Guidelines - IVIG Resistance
![Page 38: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/38.jpg)
Page 37
xxx00.#####.ppt 4/10/19 10:37:58 AMPediatric Cardiology Pediatric
Problems with 2017 Guidelines
•No robust data from clinical trials for IVIG resistance
•No guidelines for sickest patients: children < 1 year of age, KD shock syndrome, severe CA abnormalities or macrophage activation syndrome
•Persistent disease (worsening labs, persistent to worsening symptoms) in the absence of fever
![Page 39: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/39.jpg)
Page 38
xxx00.#####.ppt 4/10/19 10:37:59 AMPediatric Cardiology Pediatric
Children <1 Year of Age•These children are at greater risk of treatment failure and CA abnormalities
-Hispanics with worse outcomes
-61% male, 39% female
•Unpublished PHIS data (14,325 pts from 2004-2014): -<6 months – 5.9% (852)
-6 - 12 months – 11.1% (1,595)
•Delayed diagnosis due to paucity of signs - Incomplete KD
-May present in shock
![Page 40: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/40.jpg)
Page 39
xxx00.#####.ppt 4/10/19 10:38:00 AMPediatric Cardiology Pediatric
•“Kawashocki”-Hypotension plus KD symptoms
- Incidence of ≈ 7%
•Compared to typical KD patients -Higher CRP, hyponatremia, hypoalbuminemia and thrombocytopenia
-↑IVIG resistance
-↑rates of CA abnormalities
- Increased risk of MR and prolonged myocardial dysfunction
Kawasaki Disease Shock Syndrome (KDSS)
Kanegaye JT, et al. Pediatrics. 2009;123:e783–e789.
![Page 41: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/41.jpg)
Page 40
xxx00.#####.ppt 4/10/19 10:38:01 AMPediatric Cardiology
KDSS
2017 Guidelines
•Initial IVIG and ASA
•Guidelines hint that KDSS
are IVIG resistant
•If IVIG resistant proceed
with options 1,2, 3 or 4,
etc
TCH
Additional therapy driven by clinical
course
2nd dose of IVIG if IVIG resistant [2]
Initial IVIG and ASA w/ IV methylprednisolone 30 mg/kg x (3
pulses) w/ oral steroid taper
![Page 42: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/42.jpg)
Page 41
xxx00.#####.ppt 4/10/19 10:38:02 AMPediatric Cardiology
KD with Severe CA Abnormalities 2017 Guidelines
•No guidelines
•Only case reports with limited outcomes
•Worrisome since these patients are at greatest risk of morbidity and mortality
TCH
IV methylprednisolone 30 mg/kg x (3 pulses) w/ oral steroid taper and infliximab vs other anakinra
+/- 2nd dose of IVIG [1] if IVIG resistant
Initial IVIG and ASA
![Page 43: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/43.jpg)
Page 42
xxx00.#####.ppt 4/10/19 10:38:03 AMPediatric Cardiology
Persistent Features w/o Fever
2017 Guidelines
•No guidelines outside of initial therapy
TCH
Additional therapy driven by clinical course
IV methylprednisolone 30 mg/kg x (~3 pulses) w/ oral
corticosteroid taper [2]
Initial IVIG and ASA
![Page 44: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/44.jpg)
Page 43
xxx00.#####.ppt 4/10/19 10:38:04 AMPediatric Cardiology Pediatric
•Most common in first 45 days
•Contributing factors:- thrombocytosis
- increased platelet adhesion
- inflammation
-endothelial dysfunction
-abnormal flow conditions
Thromboprophylaxis in KD
![Page 45: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/45.jpg)
Page 44
xxx00.#####.ppt 4/10/19 10:38:05 AMPediatric Cardiology Pediatric
•Aspirin – low dose until coronary artery normalization
•Clopidogrel - increased risk of thrombosis or aspirin non-responder
•Lovenox - the anti-inflammatory actions and anticoagulant effects
Thromboprophylaxis in KD
![Page 46: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/46.jpg)
Page 45
xxx00.#####.ppt 4/10/19 10:38:06 AMPediatric Cardiology Pediatric
2017 guidelines –KD Risk Evaluation
![Page 47: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/47.jpg)
Page 46
xxx00.#####.ppt 4/10/19 10:38:07 AMPediatric Cardiology Pediatric
2017 Guidelines - Echo Surveillance
• Twice weekly while rapidly expanding
• First 45 days: weekly• First 3 months:
monthly• Every 3 months for
first year
Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease: A Scientific Statement from the AHA. 2013; Circulation
![Page 48: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/48.jpg)
Page 47
xxx00.#####.ppt 4/10/19 10:38:07 AMPediatric Cardiology Pediatric
Kawasaki Disease Follow Up
![Page 49: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/49.jpg)
Page 48
xxx00.#####.ppt 4/10/19 10:38:09 AMPediatric Cardiology Pediatric
Kawasaki Disease Follow Up
![Page 50: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/50.jpg)
Page 49
xxx00.#####.ppt 4/10/19 10:38:10 AMPediatric Cardiology Pediatric
Kawasaki Disease Follow Up
![Page 51: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/51.jpg)
Page 50
xxx00.#####.ppt 4/10/19 10:38:11 AMPediatric Cardiology Pediatric
Kawasaki Disease Follow Up
![Page 52: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/52.jpg)
Page 51
xxx00.#####.ppt 4/10/19 10:38:13 AMPediatric Cardiology Pediatric
Kawasaki Disease Follow Up
![Page 53: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/53.jpg)
Page 52
xxx00.#####.ppt 4/10/19 10:38:15 AMPediatric Cardiology Pediatric
•At TCH
- Infrequent follow-up throughout childhood
•Echocardiogram
•Electrocardiogram
•Clinic visit
•If sports – perfusion imaging (cMRI)
Kawasaki Disease Follow Up
![Page 54: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/54.jpg)
Page 53
xxx00.#####.ppt 4/10/19 10:38:16 AMPediatric Cardiology Pediatric
Rheumatology Follow Up
•Children < 1 year or any child with a complicated KD course
•Follow up labs (i.e., CBC, LFTs, inflammatory markers, albumin, sodium) and clinical course
•Tapering of corticosteroids and other therapies if necessary, are based on improvement of labs and collaboration with cardiology
![Page 55: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/55.jpg)
Page 54
xxx00.#####.ppt 4/10/19 10:38:17 AMPediatric Cardiology Pediatric
•Defer live virus vaccines for 11 months -MMR -Varicella-Flumist-Rotavirus-Zoster
-Smallpox
-Yellow fever
2017 Guidelines –Immunizations After IVIG in KD
![Page 56: Kawasaki Disease · Pediatric Cardiology S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 Kawasaki Disease: What you need to](https://reader033.vdocuments.us/reader033/viewer/2022041602/5e31dbb0111bc6768f09543b/html5/thumbnails/56.jpg)
Page 55
xxx00.#####.ppt 4/10/19 10:38:17 AMPediatric Cardiology Pediatric
Thank you